MaxCyte rises on collaboration with Imugene for cancer medicines
** Shares of cell engineering firm MaxCyte MXCT.O rise ~4.2% to $5.18
** Firm says it signed an agreement allowing Imugene IMU.AX to use MaxCyte's Flow Electroporation technology and ExPERT platform to develop its cancer medicines
** Says it is entitled to receive platform licensing fees and program-related revenue in return
MaxCyte rises on collaboration with Imugene for cancer...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.001(1.45%) |
Mkt cap ! $519.7M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.1¢ | 6.8¢ | $804.4K | 11.58M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 508192 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 2356842 | 29 |
View Market Depth
| Last trade - 11.49am 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.0¢ |
Change
0.001 ( 1.16 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 7.1¢ | 6.8¢ | 5566714 | ||
| Last updated 12.09pm 21/05/2024 ? | |||||
| IMU (ASX) Chart |